There were no significant correlations between plasma PGRN or IL-6 levels and age at onset in patients with FTLD (overall or stratified clinically or genetically), AD, or in control subjects, or between IL-6 levels and (current) duration of illness in patients with FTLD (separately or combined, clinically or genetically) or AD. The gene discussed is IL6; the disease is Alzheimer disease.